SOTIO is conducting a Phase 1/2 (EudraCT number: 2021-005873-25), first-in-human, open label, multicentered clinical trial to assess the safety and preliminary efficacy of SOT102 in monotherapy and in combination with established standard of care therapies (SoC). The trial will enroll patients with gastric adenocarcinoma and adenocarcinoma of the gastroesophageal junction (GEJ) and pancreatic adenocarcinoma across sites in EU and the United States. More information about CLAUDIO-01 clinical trial can be found here.